Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease

International Journal of Impotence Research

Volumn 20, Issue 2, 2008, Pages 150-156

  Park, J W ^a,b   Leithauser B ^a   Mrowietz, C ^b   Jung, F ^b,c  

^a Hoyerswerda Hospital   (Germany)

^b Institute for Heart and Circulation Research   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Endothelial dysfunction; Erectile dysfunction; Microcirculation; Nailfold capillary microscopy; Phosphodiesterase inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TADALAFIL; WARFARIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; ERECTILE DYSFUNCTION; ERYTHROCYTE; FLUSHING; HEADACHE; HUMAN; HYPEREMIA; MALE; MICROCIRCULATION; MICROSCOPY; MYALGIA; PENIS ERECTION; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; BLOOD FLOW VELOCITY; CARBOLINES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; MALE; MICROCIRCULATION; MICROSCOPY; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PREDICTIVE VALUE OF TESTS; SKIN;

EID: 40649090202     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901538     Document Type: Article

References (48)

1. Billups KL. Erectile dysfunction as an early sign of cardiovascular disease. Int J Impot Res 2005; 17(Suppl 1): S19-S24.
2. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-253.
3. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006; 4: 53-65.
4. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: II27-II33.
5. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190: 244-254.
6. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005; 32: 379-935.
7. Esposito K, Giugliano D. Obesity, the metabolic syndrome, and sexual dysfunction. Int J Impot Res 2005; 17: 391-398.
8. Kuthe A, Wiedenroth A, Magert HJ, Uckert S, Forssmann WG, Stief CG et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol 2001; 165: 280-283.
9. Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 1987; 79: 170-174.
10. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179-184.
11. Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res 2006; 18: 55-60.
12. Elesber AA, Solomon H, Lennon RJ, Mathew V, Prasad A, Pumper G et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006; 27: 824-831.
13. Jung F, Kolepke W, Spitzer S, Kiesewetter H, Ruprecht KW, Bach R et al. Primary and secondary microcirculatory disorders in essential hypertension. Clin Investig 1993; 71: 132-138.
14. Koscielny J, Latza R, Wolf S, Kiesewetter H, Jung F. Early rheological and microcirculatory changes in children with type I diabetes mellitus. Clin Hemorheol Microcirc 1998; 19: 139-150.
15. Ishibashi Y, Takahashi N, Shimada T, Sugamori T, Sakane T, Umeno T et al. Short duration of reactive hyperemia in the forearm of subjects with multiple cardiovascular risk factors. Circ J 2006; 70: 115-123.
16. Shamim-Uzzaman QA, Pfenninger D, Kehrer C, Chakrabarti A, Kacirotti N, Rubenfire M et al. Altered cutaneous microvascular responses to reactive hyperaemia in coronary artery disease: a comparative study with conduit vessel responses. Clin Sci (Lond) 2002; 103: 267-273.
17. Bonetti PO, Pumper GM, Higano ST, Holmes Jr DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137-2141.
18. Simonsen U, Garcia-Sacristan A, Prieto D. Penile arteries and erection. J Vasc Res 2002; 39: 283-303.
19. Park JW, Mrowietz C, Chung N, Jung F. Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study. Clin Hemorheol Microcirc 2004; 31: 173-183.
20. Sommer F, Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol 2005; 23: 385-392.
21. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur Urol 2006; 49: 979-986.
22. de Tejada IS. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res 2004; 16(Suppl 1): S40-S42.
23. Gruenwald I, Shenfeld O, Chen J, Raviv G, Richter S, Cohen A et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006; 50: 134-140.
24. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy 'non-responders' to tadalafil and vardenafil: a real-life study. Eur Urol 2006; 50: 126-132.
25. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999; 33: 1756-1824.
26. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
27. Klyscz T, Jünger M, Jung F, Zeintl H. Cap image - a new kind of computer-assisted video image analysis system for dynamic capillary microscopy. Biomed Technik 1997; 42: 168-175.
28. Salerud EG, Tenland T, Nilsson GE, Oberg PA. Rhythmical variations in human skin blood flow. Int J Microcirc Clin Exp 1983; 2: 91-102.
29. Ostergren J, Fagrell B. Skin capillary blood cell velocity in patients with arterial obliterative disease and polycythaemia: a disturbed reactive hyperaemia response. Clin Physiol 1985; 5: 35-43.
30. Jung F, Toonen H, Mrowietz C, Wolf S, Kiesewetter H, Wenzel E et al. Error analysis, biological modification factors and variance of peri-ungual video-capillary microscopy]. Biomed Tech (Berl) 1990; 35: 195-204.
31. Berg B, Solberg HE, Nilsson JE, Tryding N. Practical experience in the selection and preparation of reference individuals: empirical testing of the provisional Scandinavian recommendations. In: Gräsbeck R, Alström T (eds). Reference Values in Laboratory Medicine. John Wiley & Sons: New York, 1981.
32. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-1813.
33. Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991; 68: 1027-1034.
34. Agewall S, Henareh L, Kublickiene K. Endothelial function in conduit and resistance arteries in men with coronary disease. Atherosclerosis 2006; 184: 130-136.
35. Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-364.
36. Vlachopoulos C, Rokkas K, Ioakeimidis N, Aggeli C, Michaelides A, Roussakis G et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol 2005; 48: 996-1002.
37. Gazzaruso C, Pujia A, Solerte SB, Amici ED, Emanuele E, Falcone C et al. Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. Int J Impot Res 2006; 18: 311-315.
38. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006; 27: 2632-2639.
39. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-1240.
40. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-851.
41. Robinson SD, Ludlam CA, Boon NA, Newby DE. Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart 2006; 92: 170-176.
42. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47: 214-220.
43. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl 2005; 26: 310-318.
44. McMahon CG, Stuckey BG, Lording DW, Wittert GA, Murphy A, Shin J et al. A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebocontrolled study in Australian men. Int J Clin Pract 2005; 59: 143-149.
45. De Rose AF, Gallo F, Carmignani G. Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. Int J Impot Res 2005; 17: 76-79.
46. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 1193-1202.
47. Gerritsen ME. Functional heterogeneity of vascular endothelial cells. Biochem Pharmacol 1987; 36: 2701-2711.
48. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241.